Mithra Pharmaceuticals jumps on new pipeline updates

Mithra Pharmaceuticals SA

29/11/2021 10:14

** Shares in Mithra Pharmaceuticals  MITRA.BR  rise nearly
8% after the company reported several pipeline updates ahead of
its Investor Day, including on Donesta for menopausal women and
contraceptive drug Nextstellis  urn:newsml:reuters.com:*:nFWN2SJ00R
    ** Beyond its current development of Donesta for vasomotor
symptoms (VMS) in menopausal women in a Phase III trial, the
company will expand its clinical program to investigate the
drug's effects on vulvovaginal atrophy, skin and hair
parameters, KBC ("buy") notes 
    ** Mithra also announced a new partnership with the
preclinical stage Belgian company BCI Pharma for the development
of CSF1R kinase inhibitors 
    ** "The entry into a class of non-hormonal drugs targeting
CSF1R kinase represents a next major step in the company's
trajectory, providing new pipeline potential beyond its current
E4 molecule," KBC says
    ** Those updates "sheds more light on its strategic
positioning into the coming years," the brokerage adds 
    ** Mithra and partner Mayne Pharma also announced the
approval of their Nextstellis oral contraceptive by the
Australian Therapeutic Goods Administration (TGA)  urn:newsml:reuters.com:*:nFWN2SJ017
    ** Mithra's shares are heading for their best day since end
of July 

 (Reporting by Kate Entringer)
 ((kate.entringer@thomsonreuters.com))